David Nierengarten
Stock Analyst at Wedbush
(4.32)
# 360
Out of 5,064 analysts
208
Total ratings
53.25%
Success rate
15.58%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Outperform | $880 → $1,000 | $918.92 | +8.82% | 23 | Nov 14, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $9 → $7 | $8.21 | -14.74% | 11 | Nov 7, 2025 | |
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $1.03 | +579.61% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $92.60 | +18.79% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $39.61 | +76.72% | 14 | Oct 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $41.58 | +5.82% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $6.99 | -14.16% | 11 | Oct 13, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $105.88 | +8.61% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $2.03 | +97.04% | 1 | Sep 8, 2025 | |
| XNCR Xencor | Reiterates: Outperform | $26 | $15.87 | +63.83% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $8.91 | +146.91% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $12.39 | +101.78% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 | $5.01 | +39.61% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $7.45 | +7.38% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.09 | +426.32% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $11.95 | +125.94% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $18.53 | +78.09% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.84 | +137.16% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $18.04 | +71.84% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $66.26 | +35.83% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $40.21 | +16.89% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $11.62 | +72.12% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $29.29 | +36.57% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $24.26 | +85.49% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $0.96 | +938.64% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.13 | +475.08% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $36.76 | -72.80% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.63 | +230.58% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.21 | +156.64% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $27.30 | +541.03% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.67 | +18,626.59% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.85 | +925.64% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.88 | +141.12% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $33.59 | +123.28% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.13 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.18 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.48 | - | 3 | Nov 20, 2017 |
argenx SE
Nov 14, 2025
Maintains: Outperform
Price Target: $880 → $1,000
Current: $918.92
Upside: +8.82%
Intellia Therapeutics
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $8.21
Upside: -14.74%
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.03
Upside: +579.61%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $92.60
Upside: +18.79%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $39.61
Upside: +76.72%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $41.58
Upside: +5.82%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $6.99
Upside: -14.16%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $105.88
Upside: +8.61%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $2.03
Upside: +97.04%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $15.87
Upside: +63.83%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $8.91
Upside: +146.91%
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $12.39
Upside: +101.78%
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.01
Upside: +39.61%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $7.45
Upside: +7.38%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.09
Upside: +426.32%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $11.95
Upside: +125.94%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $18.53
Upside: +78.09%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.84
Upside: +137.16%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $18.04
Upside: +71.84%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $66.26
Upside: +35.83%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $40.21
Upside: +16.89%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $11.62
Upside: +72.12%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $29.29
Upside: +36.57%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $24.26
Upside: +85.49%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $0.96
Upside: +938.64%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.13
Upside: +475.08%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $36.76
Upside: -72.80%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.63
Upside: +230.58%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.21
Upside: +156.64%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $27.30
Upside: +541.03%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.67
Upside: +18,626.59%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.85
Upside: +925.64%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.88
Upside: +141.12%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $33.59
Upside: +123.28%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.18
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.48
Upside: -